lass III antiarrhythmic agents exert their strong antiarrhythmic effect on tachyarrhythmias by blocking potassium channels, thereby prolonging the myocardial cells' action potential duration and refractoriness. Furthermore, these agents do not affect cardiac output and are thus safe to use in patients with heart failure. Although amiodarone is more effective than sotalol in patients with atrial fibrillation (AF), ventricular tachycardia (VT) or congestive heart failure, [1] [2] [3] [4] sotalol has the advantages of simpler pharmacokinetics and fewer side-effects. 5 Sotalol is used as first-or second-line therapy for many types of tachycardia, even in patients with structural heart disease. However, according to the Japanese Circulation Society (JCS) guidelines for drug treatment of arrhythmias, sotalol is not the treatment of choice for patients with severe cardiac dysfunction. 6 In patients with congenital heart disease (CHD), tachyarrhythmias are often refractory to medical treatment and can result in sudden death, particularly in those with inoperable, cyanotic CHD, and those with single-ventricle physiology or complicated severe cardiac dysfunction. There is a relative scarcity of studies that investigate the efficacy and safety of sotalol in patients with CHD, especially in the Japanese population.
The goal of the present study was to investigate the efficacy and safety of sotalol in patients with CHD and refractory tachyarrhythmias.
Methods

Patients
From December 2002 to May 2007, 44 patients (21 females 23 male) with CHD were given oral sotalol at the National Cardiovascular Center in Japan and the clinical course of the tachyarrhythmias and efficacy of sotalol was followed retrospectively. Diagnoses of CHD consisted of univentricular heart (including hypoplastic LV or RV) in 10, tetralogy of Fallot in 12, transposition of the great arteries in 5, tricuspid stenosis or atresia in 5, corrected transposition of the great arteries in 3, Ebstein's anomaly in 3, congenital mitral valve insufficiency in 2, pulmonary atresia in 1, ventricular septal defect in 1, aortic valve stenosis and insufficiency in 1, and total anomalous pulmonary venous connection in 1.
Diagnosis of the tachyarrhythmias was based on surface ECG, 24-h ambulatory Holter monitoring or treadmill exercise tolerance test. Nonsustained tachyarrhythmias of more than 3 beats were included as the targets of treatment in this study.
Assessment of the Efficacy of Sotalol
Efficacy of antiarrhythmic therapy was judged according to clinical symptoms, follow-up 24-h ambulatory Holter monitoring, or treadmill excise tolerance testing. Complete control was defined as no recurrence of tachyarrhythmias after administration of sotalol. Partial control was defined as improvement in clinical symptoms, decreasing frequency and prolongation of cycle length, or shorter duration of Key Words: Congenital heart disease (CHD); Sotalol; Tachyarrhythmia C tachyarrhythmias. Failure was defined as discontinuation of sotalol secondary to adverse effects or the inability of therapy to modulate any parameters of the tachyarrhythmia. Changes in heart rate (HR), QRS duration, QTc and the levels of B-type natriuretic peptide/human atrial natriuretic peptide (BNP/hANP) were compared before and after administration of sotalol. Patients with a pacemaker or those receiving a -blocker with a different status before and after sotalol administration were excluded from HR analysis. Patients receiving other antiarrhythmic agents (class I or IV) were excluded from analysis of QRS duration and QTc, and patients who were started on sotalol perioperatively were excluded from analysis of BNP/hANP.
The following possible predictors of the effectiveness of sotalol were explored: age at administration, sex, follow-up period, diagnosis of tachyarrhythmia (supraventricular reentrant tachyarrhythmia only, presence of more than 2 types of tachyarrhythmia, or tachyarrhythmia combined with AF), -blocker therapy at time of administration, surgical history (number of previous surgeries, no corrective surgery, interval after corrective surgery), QRS duration, pacemaker, single-ventricle physiology, isomerism heart, clinical status (New York Heart Association (NYHA) ≥III), and BNP level ≥200 pg/ml.
Statistical Analysis
Values are shown as mean ± SD unless otherwise specified. Comparisons were made with the 2-tailed unpaired Student's t-test, 1-way ANOVA, 2 , or Fisher's exact test, where appropriate. The relationship between dose and HR was analyzed using linear regression. A p-value <0.05 was considered statistically significant.
Results
Rhythm Determination and Indications for Class III Agents
Rhythms were supraventricular tachycardia (SVT) in 27 patients (61%), VT in 8 (18%), and complicated SVT/VT in 9 (20%). SVT consisted of intra-atrial reentrant tachycardia (IART) in 14 patients, atrial tachycardia (AT) in 8, atrioventricular reentrant tachycardia in 1, complicated IART/ AT in 2, complicated IART/AF in 1, and complicated IART/AF/junctional tachycardia (JT) in 1. VT consisted of nonsustained VT (NSVT) in 6 patients, sustained VT in 1, and ventricular fibrillation in 1. In the patients with complicated SVT/VT, all had NSVT, and SVT consisted of IART in 3 patients, AT in 1, IART/AT in 1, IART/AT in 3, and undiagnosed narrow QRS tachycardia in 1.
The indication for sotalol treatment was uncontrollable tachyarrhythmia despite the use of 1 or more antiarrhythmic medications in 31 patients, perioperative tachyarrhythmias in 6 patients, hemodynamically overloaded hearts in 5 patients, life-threatening tachyarrhythmia after ICD implantation in 1 patient, and tachyarrhythmia during pregnancy in 1 patient.
Characteristics of the Patients (Table 1)
Mean age of patients receiving sotalol was 23±12 years (0.1-42 years) with a follow-up period of 13±12 months. The number of previous antiarrhythmic drugs was 2±1. Study patients with CHD included those who had not undergone corrective surgery (n=5; 11%), those with single-ventricle physiology (n=17; 39%), those with isomerism heart (n=6; 14%), those with NYHA class III or IV (n=5; 11%), those with high BNP level (≥200 pg/ml: 6/42 patients, 14%), and those with wide QRS interval (≥160 ms; 14, 32%). In addition to sotalol, -blockers were administered in 14 patients, digoxin in 8, verapamil in 1, aprindine in 1, and flecainide in 1. (Fig 1) One of the patients had previously received amiodarone, but it was ineffective. Complete control of tachyarrhythmias was achieved in 18 patients (41%), partial control was achieved in 15 (34%), and failure occurred in 11 (25%) in response to therapy with sotalol alone. Eight patients underwent non-pharmacological interventions (eg, surgical intervention, pacemaker implantation, or catheter ablation), which resulted in improved efficacy of sotalol in 6 patients. The addition of amiodarone to sotalol improved efficacy in 1 patient. Thus, the final efficacy of sotalol was complete control in 23 patients (52%), partial control in 14 (32%) and failure in 7 (16%). Four patients with complete control discontinued sotalol during follow-up; 5 of 7 patients with failure on sotalol were transitioned to amiodarone, with 1 subsequent death because of torsades de pointes (TdP), and 1 patient had persistent AT and AF.
Efficacy of Sotalol
Dosage
Sotalol was started with a relatively low initial dose (46 mg·m -2 ·day -1 divided into 3 doses for infants, and 2 doses for children and adults) with the dose increases every week as needed after recording clinical symptoms, HR, and QT interval (mean maintenance dose: 88 mg· m -2 ·day -1 ) (Fig 2A) . The maintenance dose was lower in patients with complete control than in patients with partial control or failure ( Fig 2B) .
Effects on HR, ECG and BNP/hANP
Sotalol decreased all HR parameters on Holter monitoring and maximal HR and on treadmill excise tolerance testing, and prolonged QTc ( Table 2) . Linear regression showed a significant relationship between the dose of sotalol and minimum HR on Holter monitoring (r 2 =0.33, p=0.02). Sotalol had no significant influence on other parameters, including BNP/hANP levels. Changes in HR and QTc after sotalol did not differ among the patients with complete control, partial control or failure.
Predictors of Effectiveness of Sotalol
Characteristics of the patients with complete control, partial control and failure are shown in Table 1 . Differences in these 3 groups were observed for tachyarrhythmias combined with AF, -blocker therapy at time of administration, and NYHA ≥III. Among these parameters, there were no valuable predictors for patients with complete control. Tachyarrhythmia combined with AF was a predictor for treatment failure in response to sotalol (odds ratio, 18.3; 95% confidence interval, 1.8-189.6; p=0.0053). Four patients with a tachyarrhythmia combined with AF did not respond to sotalol; after sotalol administration, IART/AF occurred in 2 patients, AF/NSVT in 1, and NSVT/TdP in 1.
Non-Pharmacological Interventions
Nine patients underwent non-pharmacological intervention combined with sotalol therapy (Table 3 ). Surgical procedures were performed in 3 patients, with the Maze procedure performed in 2 of them. The Maze procedure was unable to be performed in 1 patient secondary to extremely large right atrium and ventricle. Pacemaker implantation was performed in 5 patients, and catheter ablation was performed in 4 patients.
Non-pharmacological interventions improved the efficacy of sotalol in 6 patients and enabled withdrawal of sotalol in 1 patient.
Adverse Effects
One patient died of TdP during administration of sotalol. Although we strongly recommended surgical repair for severe congenital mitral valve insufficiency for this 34-yearold patient with Williams syndrome, severe mental retardation and renal insufficiency (serum creatinine 1.2 mg/dl), his family declined. Sotalol (240 mg, 166 mg/m 2 ) was administered for polymorphic NSVT, AT and AF. This patient died 4 months after initiation of sotalol administration and 3 weeks after the last increase in drug dose. The QTc interval was 470 ms at 2 weeks before his death.
Two patients complained of fatigue with sotalol, and sotalol therapy was ceased in 1 of them. Five patients re- III II  2  TOF  ICR  IART, NSVT  PVR  F P  I I II  3  Ebstein  TVR  IART  re-TVR, Maze  P C  I I II  4  UVH  Fontan  IART, AF, JT  F C  I I II  5  TGA  Mustard  IART  P C  I I II  6  PA  TCPC conversion  IART  F C  I I II  7  cTGA  DSO  IART, NSVT  P P  III II  8  TOF  ICR  IART  F C  I I II  9 TOF ICR IART C off I I ceiving sotalol required pacemaker implantation. Because of the inclusion of patients with latent conduction disturbance caused by unusual anatomy and hemodynamics, it was difficult to determine whether the bradycardia in these 5 patients could be attributed to the adverse effect of sotalol.
Discussion
The present study investigated the efficacy of sotalol in patients with CHD and refractory tachyarrhythmias. Antiarrhythmic agents are typically not efficacious in patients with complicated CHD, particularly those with multiple anomalies and hemodynamically overloaded hearts, and these patients sometimes require both surgical and medical treatment in order to reduce arrhythmogenicity. Indeed, 9 patients in the present study had combination therapy of sotalol and non-pharmacological interventions, which resulted in improved pharmacologic efficacy in 6 patients, and another patient was able to discontinue treatment with sotalol. Thus, non-pharmacological interventions based on the hemodynamic evaluation should be considered for patients with refractory tachyarrhythmias.
The efficacy of sotalol in pediatric populations has been investigated, including in those with structurally normal hearts [7] [8] [9] [10] (Table 4 ). Although the efficacy of sotalol in the present study of a Japanese population was similar to that in previous reports, the maintenance dose was relatively lower in the present study. It is likely that the optimal dose of sotalol differs between patients of different ethnicities. For example, a twice-daily sotalol dose of 120 mg provided the most favorable benefit in a study of adult Caucasian, Black, and Hispanic patients, 11 whereas another study of Japanese patients reported that the optimal was 80 mg and that 40 mg was the recommended initial dose. 12 This is supported by the present patients achieving partial or complete control with a comparatively lower maintenance dose. Furthermore, the patients with complete control required a lower maintenance dose than the patients with partial control or failure. Although there were no predictors for complete control, some patients had a good response to a low dose of sotalol.
In the present study, tachyarrhythmia combined with AF was a predictor for failure to respond to sotalol. The efficacy of sotalol for maintaining sinus rhythm in patients with AF is relatively low in studies of adults. [1] [2] [3] 13 However, the mechanism of AF likely differs in patients with and without CHD, indicated by the fact that all patients with AF in the present study had complications with other tachyarrhythmias, such as IART, JT and/or VT. Tachyarrhythmia combined with AF in CHD implies progression of structural and electrophysiologic remodeling caused by impaired hemodynamics. In our study, 4 patients with tachyarrhyth-mia combined with AF failed to respond to treatment with sotalol. These patients experienced not only AF, but also IART, NSVT or TdP after administration of sotalol. Thus, sotalol may be ineffective in patients with advanced cardiac remodeling.
The dose-related adverse effects of sotalol include bradycardia mediated by -adrenergic blockade, QT prolongation with reverse use dependence, and proarrhythmia with risk of TdP. 5, 12, 14 In this study, 2 patients had to discontinue sotalol secondary to adverse effects (TdP and fatigue). However, sotalol did not affect BNP/hANP levels, even in those with complicated CHD and severe heart failure. This favorable safety profile may be related to our starting sotalol at a lower dose and maintaining it at a relatively low dose, compared with other trials of sotalol.
One patient with severe congestive heart failure and mitral insufficiency, multifocal tachyarrhythmias, and renal failure died secondary to TdP. TdP occurs in 2.4% of those receiving sotalol, mostly within the first week of initial treatment or after dose adjustment. 5, 15 Risk factors for TdP include female gender, sustained VT/ventricular fibrillation, history of congestive heart failure, sotalol dose >320 mg/day, and elevated baseline serum creatinine. 5 In this case, TdP occurred more than 1 week after the last increase in the sotalol dose. The causation is unclear and in retrospect, amiodarone, with its lower reverse use-dependence and lower effects on renal function, would have been a better choice for this patient.
Among the class III agents, amiodarone is more effective than sotalol in pediatric patients. [16] [17] [18] [19] [20] However, it can produce pulmonary toxicity and disturbances of thyroid function. 5, 14 Because amiodarone is a highly lipophilic compound and affects multiple organ systems during long-term administration, 5 its use should be considered more carefully in younger patients who are not expected to reach the endpoint of administration. Compared with amiodarone, sotalol has the advantage of relatively simple pharmacokinetics. Peak plasma concentrations occur 2-4 h after oral dosing, and most adverse effects occur within the first week after initiation of treatment. 5 Therefore, sotalol is useful even for patients with perioperative hemodynamic instability. We use sotalol as the first-line therapy for refractory tachyarrhythmias in patients with CHD, including in the perioperative setting, whereas amiodarone is used as first-line therapy for patients with severe heart failure or a history of syncope or near-sudden death.
Conclusion
In the present study, sotalol was partially or completely effective for the treatment of refractory tachyarrhythmias in patients with CHD. Further, this therapy was well tolerated, Recurrence-free interval of 2 years was 81% even in patients with severe heart disease (eg, inoperable heat disease, cyanotic heart disease, single-ventricle physiology, and NYHA class III or IV), and non-pharmacological interventions in these patient improved the response to sotalol.
These findings suggest that sotalol is useful and effective for decreasing the frequency of tachyarrhythmias in patients with CHD, including those with multiple anomalies and with hemodynamically overloaded hearts. The combination of non-pharmacological interventions and sotalol should be considered for the treatment of refractory tachyarrhythmias in patients with CHD. Further study in larger patient populations and with longer follow-up would be of benefit to validate these results.
